Nicholas Landekic
Directeur Général chez PolyMedix Pharmaceuticals, Inc.
Profil
Nicholas Landekic founded PolyMedix, Inc. in 2002, where he worked as President, Chief Executive Officer & Director from 2011 to 2013.
Mr. Landekic also currently works at PolyMedix Pharmaceuticals, Inc., as President & Chief Executive Officer from 2002.
Mr. Landekic also formerly worked at Locus Pharmaceuticals, Inc., as President & Chief Executive Officer from 2000 to 2002, Cephalon, Inc., as Senior Director-Business Development from 1991 to 1995, Bristol Myers Squibb Co., as Senior Manager-Strategic Marketing from 1988 to 1991, and Guilford Pharmaceuticals, Inc., as SVP-Corporate Development & Investor Relations from 1995 to 2000.
Mr. Landekic received his graduate degree from Indiana University, undergraduate degree from Marist College, and Masters Business Admin degree from State University of New York at Albany.
Postes actifs de Nicholas Landekic
| Sociétés | Poste | Début |
|---|---|---|
| PolyMedix Pharmaceuticals, Inc. | Directeur Général | 06/05/2011 |
Anciens postes connus de Nicholas Landekic
| Sociétés | Poste | Fin |
|---|---|---|
| POLYMEDIX, INC. | Fondateur | 30/01/2013 |
Locus Pharmaceuticals, Inc.
 Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | President | 01/01/2002 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Public Communications Contact | 01/01/2000 |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | 01/01/1995 |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | 01/01/1991 |
Formation de Nicholas Landekic
| Indiana University | Graduate Degree |
| Marist College | Undergraduate Degree |
| State University of New York at Albany | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 5 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
PolyMedix, Inc.
 PolyMedix, Inc. Pharmaceuticals: MajorHealth Technology PolyMedix, Inc. engaged in developing first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company was founded in 2002 and was headquartered in Radnor, PA. | Health Technology |
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
| PolyMedix Pharmaceuticals, Inc. |
